Monday, 31 August 2026European Markets

BASILIX CERT Stock Falls By 29% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of BASILIX CERT (BEL 20: BAS.BR) dropped by a staggering 29.33% in 21 sessions from €15 to €10.60 at 04:11 EST on Thursday, after five successive sessions in a row of losses. BEL 20 is dropping 2.65% to €3,629.91, after five successive sessions in a row of losses.

About BASILIX CERT

Basilix Cert owns and operates a shopping center in Belgium. The company operates accessories, feed, beauty, jewelry, fashion, multimedia, and house shops, as well as restaurants. It offers products of approximately 40 brands. The company was founded in 1984 and is based in Brussels, Belgium. Basilix Cert is a subsidiary of KBC Bank NV.

Volatility

BASILIX CERT's last week, last month's, and last quarter's current intraday variation average was a negative 5.19%, a negative 9.10%, and a positive 16.91%.

BASILIX CERT's highest amplitude of average volatility was 5.19% (last week), 9.10% (last month), and 16.91% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BASILIX CERT's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for BASILIX CERT is 10 which is 23.07% below its average volume of 13.

More news about BASILIX CERT (BAS.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com